CCCleo Lina Crunelle

Cleo Lina Crunelle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cleo Lina Crunelle has a total of 384 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Patient-Reported Outcome Measures (PROMs) During and After Residential Substance Use Disorder Treatment: A Prospective Cohort Study in Belgium

    by Amine Zerrouk, Charlotte Migchels, Clara De Ruysscher, Jerome Antoine, Kim Fernandez, Frieda Matthys, Wim van Den Brink, Cleo L. Crunelle, Wouter Vanderplasschen

    This prospective multicenter cohort study examined changes in patient-reported outcome measures (PROMs) among 161 men and women entering residential substance use disorder (SUD) treatment in Belgium and explored how treatment setting and sociodemographic factors influence outcomes. PROMs were assessed at baseline and after 45, 90, and 180 days using the PROMIS-GH (general health), WHOQoL-BREF (quality of life), and SURE-NL (recovery). Linear mixed models showed significant improvements in mental and physical health, and in all quality of life (QoL) domains except for social relationships. Psychological and physical health improvements plateaued, while perceived QoL and environmental domains improved linearly. Males scored higher in psychological health whereas treatment modalities differed in psychological health and social relationships. Recovery scores remained consistently high, possibly due to ceiling effects, underscoring the importance of the timing and context of PROM assessment. Integrating PROMs into routine care has the potential to support patient-centered practices and enhance treatment outcomes in SUD services.

  • Top Cited Papers
    Open Access

    Predictors of treatment success in patients with substance use disorder (SUD) and co-morbid attention deficit/hyperactivity disorder (ADHD): Results from the International Naturalistic Cohort Study of ADHD and SUD (INCAS)

    by Christoffer Brynte, Arnt Schellekens, Maija Konstenius, Alex Hendrikus Abraham Begeman, Cleo Lina Crunelle, Zsolt Demetrovics, Geert Dom, Romain Icick, Brian Johnson, Máté Kapitány-Fövény, et al.


  • Religiousness and self-control in patients with substance use disorder (SUD) and comorbid attention deficit/hyperactivity disorder (ADHD)

    by Alex Ha Begeman, Arnt Schellekens, Wim van Den Brink, Csaba Barta, Christoffer Brynte, Cleo L Crunelle, Laura De Fuentes-Merillas, Zsolt Demetrovics, Geert Dom, Johan Franck, et al.

    Background: Religiousness has been positively associated with better mental health and stronger self-control, including in patients with substance use disorders (SUDs) or attention deficit/hyperactivity disorder (ADHD). However, data on religiousness in patients with SUD and comorbid ADHD are lacking. Objectives: This study aims to test in patients with SUD and comorbid ADHD whether (1) religiousness is negatively associated with SUD and ADHD symptom severity, and (2) self-control mediates the assumed negative association of religiousness with SUD and ADHD symptom severity. Method: In an international cohort study, baseline religiousness, self-control, SUD and ADHD symptom severity, and craving were assessed with self-report questionnaires and structured clinical interviews in 578 treatment-seeking SUD patients with comorbid adult ADHD (SUD + ADHD). Data were analyzed using structural equation modeling (SEM). Results: Stronger self-control wad associated with lower severity of both ADHD and SUD, but higher religiousness was only associated with lower severity of ADHD. This association was not mediated by self-control. Conclusion: Religiousness may have a salutary relationship with ADHD severity, but not with SUD severity. While self-control was associated with lower symptom severity for both co-occurring conditions, it may not be involved in the potentially salutary effects of religiousness in patients with SUD + ADHD.


  • Open Access

    Incorporating Patient-Reported Outcome Measures and Patient-Reported Experience Measures in Addiction Treatment Services in Belgium: Naturalistic, Longitudinal, Multicenter Cohort Study

    by Amine Zerrouk, Charlotte Migchels, Clara De Ruysscher, Kim Fernandez, Jerome Antoine, Florian De Meyer, Frieda Matthys, Wim van Den Brink, Cleo Lina Crunelle, Wouter Vanderplasschen

    Background: Traditionally, treatment outcomes of service users with a substance use disorder (SUD) are measured using objective and provider-reported indicators. In recent years, there has been a shift toward incorporating patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) to capture service users’ perspectives on treatment outcomes and experiences. Objective: The OMER-BE (Outcome Measurement and Evaluation as a Routine Practice in Alcohol and Other Drug Services in Belgium) study evaluates the acceptability and feasibility of PROMs and PREMs in different SUD treatment services, using the recently developed International Consortium for Health Outcomes Measurement Standard Set for Addictions. This paper presents the design and baseline characteristics of the study, indicators of attrition at 45-day follow-up, and the feasibility of the implementation of PROMs and PREMs in residential and outpatient services. Methods: A convenience sample of 189 treatment-seeking individuals with SUD from different inpatient (therapeutic communities and psychiatric centers) and outpatient treatment services was followed for six months. Sociodemographic characteristics; clinical factors; and PROMs including recovery strengths, quality of life, and global health were assessed at baseline and within 3 weeks after starting treatment. Additionally, PROMs and PREMs were measured 45, 90, and 180 days later. Comparisons were made between treatment modalities, and indicators of attrition at the 45-day follow-up were assessed using ANOVA and chi-square tests. Results: Baseline differences were observed between the three treatment modalities regarding education, SUD treatment history, primary substance, and Attention-Deficit/Hyperactivity Disorder Self-Report scores. Overall, patients in psychiatric treatment centers had a higher education level and less polysubstance use, while outpatients had fewer previous SUD treatments but received relatively more often opioid agonist treatment. Inpatients reported more attention-deficit/hyperactivity disorder symptoms and higher SUD severity than outpatients. Additionally, recovery strength scores were significantly lower in the outpatient group compared to the other groups, particularly in the subdomains of “Substance Use,” “Self-care,” and “Outlook on Life.” At the 45-day follow-up assessment, the attrition rate was 36.6%. Comparisons between participants who completed the 45-day follow-up and those who dropped out revealed that completers were significantly older, had a higher level of education, were more likely to live alone, and were more likely to have a mother born in Belgium. They also had higher average scores on the “Material Resources” domain of the Substance Use Recovery Evaluator, which includes questions about stable housing, a steady income, and effective financial management. Conclusions: Evaluating PROMs and PREMs appears to be feasible in a diverse group of treatment-seeking patients with SUD in Belgium. However, challenges remain for structural implementation in practice, especially in outpatient services. Routine monitoring of PROMs and PREMs has the potential to empower patients, service providers, and policy makers by providing a comprehensive understanding of service users’ needs and treatment effectiveness.


  • Open Access

    Psychometric Evaluation of the Dutch Version of the Substance Use Recovery Evaluator (SURE-NL)

    by Charlotte Migchels, Wim van Den Brink, Amine Zerrouk, Frieda I.A. Matthys, Clara De Ruysscher, Dries Debeer, Wouter Vanderplasschen, Cleo Lina Crunelle

    Introduction: Patient-reported outcome measures (PROMs) are an important source of information that allow for a patient-centered assessment. Outcome measurement of substance use disorder (SUD) treatment traditionally focuses on drug use and deficits in functioning, overlooking other aspects of the personal and dynamic process of recovery. The substance use recovery evaluator (SURE) is a PROM developed with service user input to monitor the recovery journey and assess treatment outcomes in people with SUD. The objective of this study was to examine the validity and reliability of the Dutch translation of the SURE, the SURE-NL, for measuring indicators of recovery in Dutch-speaking patients with SUD. Methods: The original SURE questionnaire was translated from English to Dutch using forward-backward translation. A total of N = 171 participants were recruited as part of a naturalistic multicenter study in inpatient (N = 149) and outpatient (N = 22) SUD treatment centers. We examined the factorial structure, reliability, and concurrent and discriminant validity of the SURE-NL. Results: The original 5-factor structure of the SURE showed acceptable fit for the SURE-NL, and internal consistencies of the subscales ranged from 0.61 to 0.76; internal consistency of the total score was 0.83. Concurrent validity was confirmed through positive correlations of the SURE-NL total and subscale scores with the WHOQoL-BREF subscales, but correlations varied depending on subscale and treatment setting, with higher correlations for the outpatient compared to the inpatient subgroup. Discriminant validity was confirmed through low, mostly non-significant correlations between the SURE-NL and the DASS-21. Conclusions: Although the SURE was originally designed for outpatient settings, our findings in a predominantly inpatient sample indicate that the SURE-NL is suitable for assessing personal recovery and recovery capital in Dutch-speaking Belgian patients with SUD. However, subscales should be used and interpreted with caution. Further research is needed with larger Dutch-speaking outpatient samples and the development of a tailored SURE for inpatient settings should be considered.


  • Effectiveness of pain medication tapering in chronic pain patients: a systematic review and meta-analysis

    by Elke Wuyts, Lisa Goudman, Cleo L. Crunelle, Maria Merlano Gomez, Koen Putman, Frenn Bultinck, Julie G. Pilitsis, Maarten Moens


  • Open Access

    Incorporating Patient-Reported Outcome Measures and Patient-Reported Experience Measures in Addiction Treatment Services in Belgium: Naturalistic, Longitudinal, Multicenter Cohort Study (Preprint)

    by Amine Zerrouk, Charlotte Migchels, Clara De Ruysscher, Kim Fernandez, Jerome Antoine, Florian De Meyer, Frieda Matthys, Wim van Den Brink, Cleo Lina Crunelle, Wouter Vanderplasschen

    BACKGROUND Traditionally, treatment outcomes of service users with a substance use disorder (SUD) are measured using objective and provider-reported indicators. In recent years, there has been a shift toward incorporating patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) to capture service users’ perspectives on treatment outcomes and experiences. OBJECTIVE The OMER-BE (Outcome Measurement and Evaluation as a Routine Practice in Alcohol and Other Drug Services in Belgium) study evaluates the acceptability and feasibility of PROMs and PREMs in different SUD treatment services, using the recently developed International Consortium for Health Outcomes Measurement Standard Set for Addictions. This paper presents the design and baseline characteristics of the study, indicators of attrition at 45-day follow-up, and the feasibility of the implementation of PROMs and PREMs in residential and outpatient services. METHODS A convenience sample of 189 treatment-seeking individuals with SUD from different inpatient (therapeutic communities and psychiatric centers) and outpatient treatment services was followed for six months. Sociodemographic characteristics; clinical factors; and PROMs including recovery strengths, quality of life, and global health were assessed at baseline and within 3 weeks after starting treatment. Additionally, PROMs and PREMs were measured 45, 90, and 180 days later. Comparisons were made between treatment modalities, and indicators of attrition at the 45-day follow-up were assessed using ANOVA and chi-square tests. RESULTS Baseline differences were observed between the three treatment modalities regarding education, SUD treatment history, primary substance, and Attention-Deficit/Hyperactivity Disorder Self-Report scores. Overall, patients in psychiatric treatment centers had a higher education level and less polysubstance use, while outpatients had fewer previous SUD treatments but received relatively more often opioid agonist treatment. Inpatients reported more attention-deficit/hyperactivity disorder symptoms and higher SUD severity than outpatients. Additionally, recovery strength scores were significantly lower in the outpatient group compared to the other groups, particularly in the subdomains of “Substance Use,” “Self-care,” and “Outlook on Life.” At the 45-day follow-up assessment, the attrition rate was 36.6%. Comparisons between participants who completed the 45-day follow-up and those who dropped out revealed that completers were significantly older, had a higher level of education, were more likely to live alone, and were more likely to have a mother born in Belgium. They also had higher average scores on the “Material Resources” domain of the Substance Use Recovery Evaluator, which includes questions about stable housing, a steady income, and effective financial management. CONCLUSIONS Evaluating PROMs and PREMs appears to be feasible in a diverse group of treatment-seeking patients with SUD in Belgium. However, challenges remain for structural implementation in practice, especially in outpatient services. Routine monitoring of PROMs and PREMs has the potential to empower patients, service providers, and policy makers by providing a comprehensive understanding of service users’ needs and treatment effectiveness.

  • Baclofen during alcohol detoxification reduces the need for additional diazepam: a randomized placebo-controlled trial

    by Cleo L Crunelle, Sami Jegham, Nathalie Vanderbruggen, Frieda Matthys

    Baclofen may reduce the symptoms of alcohol withdrawal, as an alternative or as an adjuvant for benzodiazepines, but the available data are insufficient to support baclofen-assisted alcohol withdrawal. This study investigated the need for diazepam during acute alcohol withdrawal in patients receiving baclofen. In a single-blind, dose-dependent randomized controlled trial with three study arms, 63 patients with alcohol use disorder, starting in-patient benzodiazepine-assisted alcohol detoxification, were randomly assigned to receive placebo (n = 18), baclofen 30 mg/day (N = 20), or baclofen 60 mg/day (N = 25) for 7 days. Diazepam was provided as needed based on the withdrawal symptoms stated by Clinical Institute Withdrawal Assessment for Alcohol-revised. The primary outcome measure was the number of patients in need of diazepam during alcohol detoxification. Secondary outcome measure included the between-group difference in the amount of diazepam needed during alcohol detoxification. Using baclofen 60 mg/day, 32% of patients needed additional diazepam compared to 35% on baclofen 30 mg/day and compared to 72% on placebo (P = .013). The median total amount of diazepam needed was significantly lower in patients receiving baclofen 60 mg/day (0 ± 10 mg diazepam) and baclofen 30 mg/day (0 ± 10 mg diazepam) compared to placebo (10 ± 43 mg diazepam; P = .017). Adverse events were comparable between patients on baclofen and placebo. Baclofen can reduce the withdrawal symptoms during alcohol detoxification. Baclofen was well tolerated and may be considered for the management of alcohol withdrawal syndrome, especially useful in situations where benzodiazepines should be withheld, such as patients with liver impairment.


  • Remote Consultations for Mental Health: Patient Experiences

    by Cleo L. Crunelle, Tom Van Daele, Sven Van Laere, Stefaan Blancke, Nathalie Vanderbruggen, Frieda Matthys

    Objective An exponential implementation of remote mental health care has been observed, but little data is available on experiences and barriers of remote health from a patient’s perspective. This study investigated experiences associated with several forms of remote consultations (both telephone and online video) for mental health care during the COVID-19 coronavirus pandemic with a particular focus on patients’ experiences. Methods This study includes results of an online web-based survey filled in by 512 patients on the use and experiences of remote mental health consultations and circulating between March and October 2021. Results Psychiatric consultations were initiated by the health care provider in 47.0% of cases, while psychological consultations were most often initiated in shared decision with the patient (54.9%). Only 28.8% of participants mentioned advantages regarding teleconsultations over face-to-face, compared to 39.3% for online video consultations. Moreover, 49.3% saw clear disadvantages for teleconsultations and 32.7% for video consultations. Positive factors associated with remote mental health care included when faced with transportation problems, followed by consultations primarily focusing on medication (for telephone consultations) or on more practical aspects (for video consultations). 25.0% of patients deemed conversations when being angry or sad to be feasible by telephone, and 33.0% considered these feasibly using video consultations. Conclusion Remote consultations were deemed feasible, but the positive factors did not seem to outweigh the face-to-face contacts from a patient’s perspective. Remote consultations will probably remain present in the following decades, although care must be taken when providing the possibility of remote mental health care.


  • Open Access

    Consensus International sur le dépistage, le diagnostic et le traitement des patients avec troubles de l’usage de substances en cas de comorbidité avec un trouble du déficit de l’attention avec ou sans hyperactivité

    by Michiel W. van Kernebeek, Florence Vorspan, Cleo L. Crunelle, Wim van Den Brink, Geert Dom, Franz Moggi, Maija Konstenius, Johan Franck, Frances R. Levin, Geurt van de Glind, et al.